Effect of Nano-Curcumin Supplementation on Cardiometabolic Risk Factors and Quality of Life

Key Findings from Clinical Trial

Researchers conducted a randomized double-blind clinical trial to investigate the effects of a highly bioavailable curcumin supplement on patients with coronary slow flow phenomenon (CSFP).

The study involved 42 patients, aged 35-70 years, with body mass index between 25 and 40 kg/m2.

Patients received either 80 mg/day nano-curcumin or a placebo for 12 weeks.

Results showed that while there were no significant improvements in certain biomarkers, curcumin supplementation prevented deterioration of glycemic control and improved physical and psychological quality of life and depression in patients with CSFP.

Practical Solutions and Value

The study suggests that nano-curcumin supplementation may offer practical solutions for improving the quality of life and mental health of patients with CSFP.

Furthermore, the findings highlight the potential value of incorporating curcumin supplements in the management of cardiometabolic risk factors and depression in this patient population.

Integration of Clinical Trials into Medical Practice

Clinical trials play a crucial role in developing safe and effective treatments. It is essential to integrate their benefits into everyday medical practice.

Platforms like DocSym, utilizing AI-driven technology, can consolidate clinical protocols and research into easily accessible knowledge bases for clinicians, facilitating the integration of evidence-based practices into patient care.

Streamlining Healthcare Operations

In today’s healthcare environment, streamlining operations is crucial. Mobile apps that support scheduling, monitoring treatments, and telemedicine can make it easier to manage patient care and expand services digitally.

By leveraging AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routine. This can lead to more efficient and effective healthcare delivery.